Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

ORPH

NASDAQ:ORPH

Orphazyme A/S

Last Close

820.10

26/07 14:59

Market Cap

32.63M

Beta: 0.80

Volume Today

25

Avg: 1.38M

PE Ratio

−0.27

PFCF: -

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics